Last updated 33 days ago

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

487 patients around the world

Available in Puerto Rico, Argentina, United States

Eli Lilly and Company

10Research sites

487Patients around the world

This study is for people with

Arterial hypertension

Obesity

From 18 Years

All Gender

Instituto de Investigaciones Clínicas Córdoba

Dean Funes 1161, Córdoba

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Av. Pueyrredon 1746, CABA, Buenos Aires

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe

Rioja 2926, Rosario, Santa Fe

Centro de Investigaciones Clínicas Baigorria

L. Paganini 324, S2152 Granadero Baigorria, Santa Fe, Argentina

INECO Neurociencias Oroño - Rosario

Bv. Oroño 1508, Rosario, Santa Fe

Instituto Médico Especializado (IME)

Hidalgo 568, CABA, Buenos Aires

Centro Especialidades Médicas SRL (CEMEDIC)

Ramón Falcón 5206, CABA, Buenos Aires

Centro Médico Santa María de la Salud

Av. del Libertador 16.131 | San Isidro | Pcia. de Bs. As.

Dorado Medical Complex

349 CALLE MENDEZ VIGO, Dorado, Puerto Rico 00646-4912

Puerto Rico Medical Research Center

OFICINA 401 TORRE MEDICA AUXILIO MUTUO PARADA 37.5 AVE PONCE DE LEON SAN JUAN, PR 00918

SponsorEli Lilly and Company

Study typeInterventional

Conditions

Arterial hypertensionObesity

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06948435